MSD

NOBLIS MSD NAMES JIM BROADWATER AS VICE PRESIDENT OF ITS NAVSEA DIVISION

Retrieved on: 
Tuesday, March 5, 2024

Reston, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today named Jim Broadwater as vice president of its Naval Sea Systems Command (NAVSEA) division.

Key Points: 
  • Reston, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today named Jim Broadwater as vice president of its Naval Sea Systems Command (NAVSEA) division.
  • Reporting to Glenn Hickok , Noblis MSD president, Broadwater will expand the company’s NAVSEA strategy to bring additional digital engineering and breakthrough technologies to its U.S. Navy partners.
  • “Jim has deep domain knowledge and an unwavering commitment to innovation, operational excellence and fiscal responsibility,” said Hickok.
  • “Under his leadership, Noblis has delivered high-value transformational solutions and rapid prototypes that help our U.S. Navy partners advance mission readiness and competitive advantage.

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Retrieved on: 
Tuesday, February 20, 2024

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points: 
  • COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).
  • Further, we are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase.
  • Using Evaxion's proprietary platform, AI-Immunology™, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.
  • The conclusion of the antigen discovery and design phases marks a significant milestone for the development of the vaccine candidate, EVX-B3.

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Retrieved on: 
Wednesday, March 6, 2024

These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ).

Key Points: 
  • These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ).
  • At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA
  • The potent antiviral activities, along with pharmacokinetic profiles of islatravir and lenacapavir, support their development as an investigational once-weekly oral combination regimen.
  • No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24.

Merck to Participate in the Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, March 5, 2024

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 3:05 p.m. EDT.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 3:05 p.m. EDT.
  • Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

Accenture Launches Accenture LearnVantage to Help Clients and Their People Gain Essential Skills and Achieve Greater Business Value in the AI Economy

Retrieved on: 
Tuesday, March 5, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240304559950/en/
    Accenture today announced the launch of Accenture LearnVantage to provide its clients with comprehensive technology learning and training services that will help them reskill and upskill their people in technology, data and AI to reinvent their organizations and achieve greater business value.
  • Accenture LearnVantage will offer tailored technology learning programs; specialized, predesigned technology academies; ecosystem learning certification services; and managed services for a client’s own learning capabilities.
  • LearnVantage also will offer nanodegrees, certified online programs designed to provide users with hands-on experience and industry-relevant skills in specialized fields.
  • “Accenture LearnVantage will help our clients not only advance their business goals but also help their people build the skills they will need for the next waves of technology change.”

Merck to Participate in the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Monday, March 4, 2024

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m.
  • ET.

Merck to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.

Key Points: 

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Retrieved on: 
Friday, February 23, 2024

The recommendation is based on results from the Phase 3 KEYNOTE-671 trial, in which neoadjuvant KEYTRUDA plus chemotherapy followed by adjuvant KEYTRUDA as a single agent after surgical resection demonstrated statistically significant and clinically meaningful improvements in overall survival and event-free survival, the study’s dual primary endpoints, versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients.

Key Points: 
  • The recommendation is based on results from the Phase 3 KEYNOTE-671 trial, in which neoadjuvant KEYTRUDA plus chemotherapy followed by adjuvant KEYTRUDA as a single agent after surgical resection demonstrated statistically significant and clinically meaningful improvements in overall survival and event-free survival, the study’s dual primary endpoints, versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients.
  • Key eligibility criteria for KEYNOTE-671 included: patients with previously untreated and resectable NSCLC at high risk of recurrence (stage II, IIIA, or IIIB [N2] by American Joint Committee on Cancer eighth edition), regardless of tumor PD-L1 expression.
  • The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union (EU), and a final decision is expected in the first half of 2024.
  • “The CHMP’s positive opinion puts us another step closer to helping certain patients in Europe with earlier stages of non-small cell lung cancer, regardless of PD-L1 expression,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
Tuesday, February 20, 2024

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.
  • The sBLA is based on data from the Phase 3 NRG-GY018 trial.
  • Health authorities in Israel, Canada, Australia, Singapore and Brazil will review this application as part of Project Orbis.
  • In endometrial cancer, Merck is evaluating KEYTRUDA in the first-line setting for advanced or recurrent disease that is dMMR (KEYNOTE-C93/ENGOT-en15/GOG-3064) and in the adjuvant setting (KEYNOTE-B21/ENGOT-en11/GOG-3053).

Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster

Retrieved on: 
Monday, February 26, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
    From left to right: Baseimmune co-founders Ariane C. Gomes (Chief Scientific Officer), Phillip Kemlo (Chief Technology Officer), and Joshua Blight (Chief Executive Officer).
  • Photo credit: Baseimmune
    “We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital.
  • This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens,” said Joshua Blight, CEO & Co-Founder, Baseimmune.
  • By using big data and a design algorithm, Baseimmune has been able to shorten the time it takes to develop a vaccine candidate.